| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PMGC Holdings Inc.
$6.66
+0.56 (+9.18%)
Market Cap
30.26 M
EPS
-2.44
P/E Ratio
-
Value Trade
177.71 K
662.89 %
Week
623.99 %
1 Month
280.57 %
3 Month
-8.26 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
204.02 K
52 Week Range
0.82 - 267.12
% held by Insiders
0 %
% held by Institutions
3.29 %
Enterprise Value
11.47 M
Total Shares
4.54 M
Short %
9.69 %
Float Shares
4.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PMGC Holdings Inc.
58Total events
2Upcoming
19Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
Event history 2
TBD
●Composition Patent FiledEL-22IP / Competition
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Elevai Enfinity Topical Exosome Serum | facial appearance improvement | — | 2024-08-26 | significant improvement noted across many aspects of skin appearance Read More | Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum Read More | |
Elevai Enfinity Topical Exosome Serum | facial appearance improvement | — | 2024-08-26 | significant improvement noted across many aspects of skin appearance Read More | Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum Read More | |
Elevai Enfinity Topical Exosome Serum | facial appearance improvement | — | 2024-08-26 | significant improvement noted across many aspects of skin appearance Read More | Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ELAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ELABFinancial Statements of A&B AEROSPACE, INC. For the three and nine months ended
A&B Aerospace, Inc. has reported positive financial results for the three and nine months ended February 28, 2026, with substantial increases in net income compared to the prior year. For the three-month period, the company achieved a net income of $123,492, a significant turnaround from a loss in the prior year, while for the nine months, net income was $343,903. Operational cash flows also showed improvement, indicating robust financial health and the ability to cover operational needs. Total assets grew markedly, helping to bolster the company's balance sheet.
Read more →ELABUPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
NorthStrive Biosciences has filed a new U.S. patent application for EL-22, a myostatin-engineered probiotic aimed at treating muscle-wasting conditions. The application covers formulations and dosing regimens for patients affected by GLP-1 receptor agonist therapy, sarcopenia, and other muscle loss issues. This move is part of the company's strategy to strengthen its intellectual property portfolio.
Read more →ELABNorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
NorthStrive Biosciences has filed a new U.S. patent application for EL-22, a myostatin-engineered probiotic technology aimed at muscle preservation in humans. This application seeks to protect a pharmaceutical product intended for patients with muscle loss linked to conditions like sarcopenia and neurological disorders. The development is part of NorthStrive's broader strategy to build its intellectual property portfolio and offers potential therapeutic solutions that address increasing concerns about muscle health.
Read more →ELAB▼ -5.5%on this news· ran to -20% by day 1shared move
NorthStrive Defense Tech Acquires Patented GPS-Denied Autonomous Drone Navigation Technology Option, Built for Defense and Counter-Unmanned Aircraft Systems Patented Software Visual-Inertial Cooperative Navigation Techno
NorthStrive Defense Tech LLC, a subsidiary of PMGC Holdings Inc., announced it has acquired an option for patented autonomous drone navigation technology designed for GPS-denied environments. This technology could enhance drone operations in defense and counter-drone applications. The acquisition marks the second contract for the company, potentially expanding its market portfolio. However, NorthStrive cannot guarantee the successful negotiation of a definitive license agreement for full commercialization.
Read more →ELABSVM Machining, Inc. Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products Co., Inc. Third Long-Term Agreement Signed by a PMGC Holdings Subsidiary in 2026, Reflecting
SVM Machining, Inc. has entered into a Long-Term Agreement with Turbo-Jet Products Co., Inc. to supply essential aerospace and defense components. This marks the third such agreement for PMGC Holdings' subsidiary in 2026. The five-year agreement enables SVM to support various defense programs while adhering to necessary federal regulations. Furthermore, the company is working towards AS9100 certification to bolster its manufacturing capabilities in regulated markets.
Read more →ELAB▼ -13.9%on this newsshared move
PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies Approxi
PMGC Holdings, Inc. has secured a $40 million equity purchase facility to accelerate its M&A strategy focused on aerospace and defense manufacturing. The company has already completed four acquisitions and aims to expand its precision manufacturing platform by leveraging favorable market dynamics. The capital will enable PMGC to pursue additional acquisitions and enhance its manufacturing capabilities to meet growing demand in these sectors. The company also looks to invest in automation and advanced manufacturing technologies while remaining open to opportunities outside its core areas.
Read more →ELAB▲ +6.1%on this news· ran to -20% by day 3
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences
NorthStrive Biosciences has announced the successful transfer of its EL-32 Working Cell Bank to a U.S. fermentation facility, marking a significant step in manufacturing optimization. This initiative aims to enhance production yield and support clinical development for its dual-action probiotic therapeutic targeting muscle preservation. The collaboration with Modulant Biosciences will facilitate process development for both human and animal health applications.
Read more →ELAB▲ +16.9%on this newsshared move
AGA Precision Systems Signs Second Long-Term Supply Agreement to Manufacture Aerospace and Defense Components for a Tier 1 Firm Signing of Second Long-Term Agreement with Major Aerospace and Defense Customer in 2026, Dem
AGA Precision Systems LLC announced a second long-term supply agreement with a Tier 1 aerospace and defense firm, formalizing a multi-year supplier-customer relationship. This agreement reflects AGA's ongoing commitment to quality and reliability in the defense supply chain. The arrangement includes commitments on quality, delivery, and pricing, appropriate for mission-critical applications. AGA aims to reinforce its reputation in the aerospace and defense sector as it continues to grow its operational visibility and recurring revenue potential.
Read more →ELAB▲ +30.4%on this news· ran to +52% by day 1shared move
PMGC Holdings Inc. [NASDAQ: ELAB] PMGC Holdings Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Multi-Sector Acquisition Strategy Facility Fully Utilized Company Mai
PMGC Holdings Inc. has announced the full utilization of a $20 million equity financing facility to strengthen its cash position and advance its acquisition strategy. With this funding, the company has completed acquisitions in precision CNC manufacturing and IT packaging sectors, enhancing its operational scale. Looking forward, PMGC plans to pursue both organic growth and additional acquisitions to maximize shareholder value and deepen its market presence. The management is committed to investing in assets that can generate sustainable cash flow.
Read more →ELAB▼ -32.9%on this newsshared move
NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications Newport Beach, California
NorthStrive Defense Tech, a subsidiary of PMGC Holdings Inc., has acquired rights to a novel drone technology designed to transport payloads across air and water. This advancement aims to enhance defense capabilities by enabling multi-domain operations. The company plans to negotiate a definitive license agreement for further commercialization, though success in these negotiations or the technology's development is not assured.
Read more →ELAB▼ -59.1%on this news· ran to -73% by day 1shared move
PMGC Holdings Inc. Announces the Formation of New Subsidiary, NorthStrive Defense Tech to Target High-Growth Defense, Drone and Autonomous Systems Sector Newport Beach, California
PMGC Holdings Inc. has announced the formation of a new subsidiary, NorthStrive Defense Tech, aimed at targeting the high-growth sectors of defense technology, particularly focusing on drones and autonomous systems. This initiative reflects PMGC's strategy to capitalize on the increasing global defense spending and the demand for innovative defense technologies. However, the company acknowledges the inherent uncertainties and risks associated with the future success of this venture, noting that there are no guarantees of revenue generation from the new subsidiary's activities.
Read more →ELAB▲ +68.3%on this news· ran to +293% by day 1shared move
AGA Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products
AGA Precision Systems has signed a long-term agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components. This contract establishes a framework for future purchases and emphasizes AGA's role in serving U.S. government contracts. The agreement is backed by AGA's recent AS9100 certification and ITAR compliance, which underscores its commitment to quality and regulatory standards in the aerospace sector.
Read more →ELAB▼ -22.5%on this news· ran to -55% by day 3
SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts
SVM Machining, Inc., a subsidiary of PMGC Holdings, has announced the successful completion of its International Traffic in Arms Regulations (ITAR) registration. This achievement enables SVM to pursue contracts within the U.S. defense and aerospace sectors, complying with necessary export-control standards. The company believes the registration strengthens its status as a qualified supplier for Tier 1 defense contractors and supports its strategy for expansion into high-value manufacturing areas. The announcement highlights SVM's commitment to delivering high-quality precision machining services across various critical industries.
Read more →ELABPMGC Holdings Inc. Announces Anticipated Reverse Stock Split
PMGC Holdings Inc. announced a 1-for-6 reverse stock split effective at 12:00 am on March 10, 2026. Following this split, the company expects to have approximately 541,461 shares of common stock outstanding. This action is part of the company's broader strategy to potentially enhance its stock value, although reverse splits can sometimes be perceived negatively by investors. The company has advised investors to be cautious, as future performance is subject to numerous uncertainties.
Read more →ELABNorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
NorthStrive Biosciences has filed ten new patent applications for its technologies, EL-22 and EL-32, aimed at enhancing muscle growth and yield in various farmed animals, including livestock, poultry, and aquatic species. The applications not only focus on boosting muscle weight return but also on the potential to reduce harmful emissions associated with livestock farming. This innovative approach could position NorthStrive favorably within the animal health and agricultural markets. The company emphasizes the implications of its technologies for sustainability and efficiency in food production.
Read more →ELABNorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health
NorthStrive Biosciences has executed a definitive license agreement with Modulant Biosciences for the commercialization of its EL-22 and EL-32 myostatin-engineered probiotics. The agreement grants Modulant exclusive rights to develop and market these products specifically for non-human animal health applications. While this represents a significant step in advancing animal health technologies, the success of commercialization and regulatory approvals remains uncertain, highlighting the inherent risks of the industry.
Read more →ELAB▼ -40%on this news
PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.
PMGC Holdings Inc. has completed the acquisition of SVM Machining, Inc., a California-based ISO 9001:2015 Certified precision machining firm. This marks PMGC's third CNC machine shop acquisition in California, aligning with its strategy to strengthen its multi-site machining platform. SVM specializes in high-quality, engineered components for critical industries, including medical and aerospace. The acquisition aims to enhance PMGC's footprint in precision manufacturing.
Read more →ELAB▼ -12.7%on this news
PMGC Holdings Inc. Announces Reverse Stock Split Effective
PMGC Holdings Inc. has announced a 1-for-4 reverse stock split effective January 6, 2026. Currently, the company has approximately 2,014,852 shares issued and outstanding, which will reduce to approximately 503,713 shares after the split. The announcement follows a prior disclosure on January 2, 2026, and includes a caution about the inherent uncertainties and risks associated with forward-looking statements. Investors are encouraged to consider the implications of the reverse stock split on their holdings.
Read more →ELAB▼ -29.7%on this news
NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries Phase III is intended to generate meaningful biological data on poten
NorthStrive Biosciences has announced the initiation of Phase III of its AI Development Program in partnership with Yuva Biosciences. This phase will focus on validating potential drug compounds identified in Phase II, aimed at treating obesity and preserving muscle health. The new phase will involve generating meaningful biological data over approximately six to nine weeks, utilizing YuvaBio's AI platform, MitoNova. The developments signify a critical step towards enhancing their therapeutic pipeline for metabolic conditions.
Read more →ELABPMGC Holdings Inc. Announces AGA Precision Systems LLC's ITAR (International Traffic in Arms Regulations) Registration Approval Newport Beach, CA
PMGC Holdings Inc. has announced that its subsidiary, AGA Precision Systems LLC, has completed the ITAR registration process. This achievement positions AGA to engage in defense and aerospace programs that require compliance with U.S. export regulations. The ITAR registration improves AGA's status as a supplier for Tier 1 defense contractors and enhances PMGC's strategic goals for growth in the defense sector.
Read more →ELABPMGC Holdings Inc.'s Subsidiary, AGA Precision Systems LLC, Completes Acquisition of Indarg Engineering, Inc. Expanding Aerospace and Defense Manufacturing Platform Strategic Acquisition Accelerates PMGC's U.S. Manufactu
PMGC Holdings Inc. announced that its subsidiary, AGA Precision Systems LLC, has successfully acquired Indarg Engineering, Inc., a CNC machining company. This strategic acquisition aims to enhance AGA's capacity to supply high-precision components for the aerospace and defense industries. The Hawthorne facility will be integrated into AGA Precision Systems, with former Indarg President Joel Alvarez continuing as General Manager, ensuring operational continuity and expertise. PMGC's acquisition strategy focuses on consolidating specialized manufacturers in the U.S. market.
Read more →ELABPMGC Holdings Inc. Terminates LOI to Focus on Acquiring High-Growth CNC Acquisitions in Aerospace, Defense, and Industrial Markets Newport Beach, CA
PMGC Holdings Inc. has terminated its earlier letter of intent to acquire a U.S.-based electronics manufacturing firm to focus on acquiring CNC machine shops in the aerospace, defense, and industrial markets. This strategic shift aims to align more closely with long-term growth and capital allocation goals. The machine shop services market is experiencing significant growth, particularly in aerospace and defense, where demand surged recently. The company is currently pursuing a pending acquisition of a certified CNC precision machining company, which is expected to bolster its portfolio in these critical sectors.
Read more →ELABPMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serv
PMGC Holdings Inc. has completed the acquisition of AGA Precision Systems LLC, a CNC machining company from California. AGA reported over $1.39 million in revenue in 2024 and is known for its high-quality manufacturing capabilities in critical sectors. The acquisition aims to enhance PMGC's growth strategy by integrating cash-flow-positive industrial businesses. Additionally, PMGC plans to invest in AGA's future expansion across defense and industrial programs, tapping into the growing CNC machine tool market.
Read more →ELABPMGC Holdings Inc. Completes Acquisition of Customer IT Packaging Company Pacific Sun Packaging with over $2,000,000 in combined revenue for fiscal years 2023 and 2024 Serves over 300 Commercial Clients including Data Ce
PMGC Holdings Inc. has successfully completed the acquisition of Pacific Sun Packaging, a company specialized in IT and electronics packaging. The total acquisition cost amounts to approximately $1.148 million, plus an additional $250,000 earnout based on revenue performance. This acquisition marks the first step in PMGC's broader strategy to acquire businesses exhibiting strong financial fundamentals. Pacific Sun's capabilities are positioned to leverage growth within the expanding IT and electronics packaging market.
Read more →ELAB▲ +5.8%on this news
PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue Serves Multiple Tier-1 Aerospace Clients AS9100- and ISO 9001-Certified CNC Manufacturer Newport Be
PMGC Holdings Inc. announced a non-binding agreement to acquire a U.S.-based CNC aerospace manufacturer specializing in high-complexity components. The target company, with a projected annual revenue of $4.5 million, is recognized for its certification and quality in the aerospace and defense sectors. This acquisition aligns with PMGC's strategy to enhance its portfolio by adding specialized U.S. manufacturers amid increasing demand in the aerospace industry. However, the deal's completion will depend on due diligence and other customary conditions, with no guarantee of finalization.
Read more →ELABPMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified US-Based CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years Acquisition Targ
PMGC Holdings Inc. has signed a Letter of Intent to acquire a profitable California-based CNC machining company with strong operational history. This acquisition is strategic for PMGC as it seeks to bolster its portfolio with businesses that have proven cash flow and industry certifications such as AS9100D and ISO 9001:2015. The target company serves key sectors including aerospace and defense, and its well-established customer relationships signify its reputation for quality. However, the deal is still contingent on various customary conditions, raising uncertainties about the closing.
Read more →ELAB▲ +21.7%on this news
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company Acquisition Target Specializes in High-Precision Electrical and Mechanical Assembly, Including Printed Circuit
PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a profitable U.S.-based electronics manufacturing company with a strong operational history. The target company specializes in high-precision electrical and mechanical assembly and has generated significant revenue and EBITDA. This acquisition is part of PMGC's strategy to capitalize on the growing momentum of domestic manufacturing and the reshoring of supply chains in the electronics sector. However, the completion of the acquisition is contingent upon customary conditions, including due diligence and corporate approvals.
Read more →ELABNorthstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22 Binding term sheet grants Modulant Biosciences exclusive global rights to develop and comme
Northstrive Biosciences has signed a binding term sheet with Modulant Biosciences, granting Modulant exclusive global rights to develop and commercialize EL-22 for animal health. This licensing deal includes the use of EL-22 as a feed additive and allows Modulant to sublicense the rights worldwide, except in South Korea. The partnership aims to explore muscle-building properties beneficial in livestock, targeting the myostatin pathway. Both companies plan to finalize a definitive licensing agreement in the coming months, pending necessary approvals.
Read more →ELABNorthstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health Newport Beach, CA
Northstrive Biosciences Inc. has strengthened its intellectual property portfolio by filing four new patent applications related to its programs EL-22 and EL-32, which target obesity treatment and animal health. The patents cover novel therapeutic approaches for muscle loss in obese patients, including potential combination therapies with GLP-1 receptor agonists. This move enhances Northstrive's position in the competitive biopharmaceutical landscape as it aims to transform obesity care and expand into animal health markets. The company now holds a total of 8 patent applications and 5 issued patents across multiple countries.
Read more →ELABNorthstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment Northstrive Biosciences recei
Northstrive Biosciences announced a positive preliminary response from the FDA regarding its IND submission for a Phase 2 clinical trial of EL-22 in combination with GLP-1 receptor agonists for obesity treatment. The feedback indicates that Northstrive's nonclinical and Phase 1 studies support the safety and activity of EL-22 in overweight and obese populations. The company plans to file the IND application in 2025 and initiate the clinical trial thereafter. This development is considered a critical milestone in addressing obesity-related challenges.
Read more →ELABPMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company Acquisition Target Currently Serves over 300 Commercial Clients, which Includes Data Centers, Technology Manufacturer
PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a profitable U.S.-based custom IT packaging company that serves over 300 commercial clients. The target company has shown consistent positive EBITDA performance and operates within a niche market, presenting opportunities for growth. PMGC anticipates completing the acquisition process, including a financial audit, by the end of Q2 2025, although the closure is subject to customary conditions and approvals.
Read more →ELABNorthstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases Northstrive Biosciences and Yuva Biosciences' collaboration will leverage MitoNova
Northstrive Biosciences has partnered with Yuva Biosciences to develop AI-powered therapies aimed at treating obesity and cardiometabolic diseases. This collaboration will focus on utilizing YuvaBio's MitoNova platform which is centered on mitochondrial science and artificial intelligence. The agreement involves a comprehensive AI Development Program that includes drug candidate identification and testing. Northstrive will gain exclusive licensing for developed technologies to enhance its pipeline in cardiometabolic diseases.
Read more →ELABPMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules
PMGC Holdings Inc. has announced a registered direct offering of its common stock, raising approximately $1.48 million. The offering includes 294,450 shares priced at $5.04 each. This move is part of the company's strategy to strengthen its financial position before the expected closing on March 24, 2025. The offering is being facilitated under Nasdaq regulations and follows a previously filed shelf registration statement with the SEC.
Read more →ELABPMGC Holdings Announces Share Repurchases from Existing Shareholders
PMGC Holdings Inc. announced that it has repurchased shares from certain existing shareholders. The company is open to further repurchases from other investors, though these actions depend on market conditions. PMGC Holdings operates a diversified portfolio and continues to explore growth opportunities, though it does not have a formal share repurchase program in place. This announcement highlights the company's engagement with shareholders amidst uncertainty in future repurchase activity.
Read more →ELABSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement "), dated as of March 7 2025, is entered into by and between [ ], a [ ] [ ] (" Seller "), and PMGC Holdings Inc. (fka Elevai Labs, Inc.),
The article details a Securities Purchase Agreement dated March 7, 2025, between a seller and PMGC Holdings Inc., formerly Elevai Labs, Inc. The agreement outlines the purchase of shares owned by the seller, specifying conditions for the transaction, including transfer of ownership and pricing based on the closing price of PMGC's common stock. The agreement also includes other legal stipulations related to representation, warranties, indemnification, and closing procedures. No specific details about the seller or the exact terms of the agreement are provided in the text.
Read more →ELABPMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance Newport Beach, Calif.
PMGC Holdings Inc. announced a 1-for-7 reverse stock split effective at midnight Eastern time to comply with Nasdaq listing requirements. This move aims to enhance their visibility and strengthen investor confidence as the company works to maintain its presence on The Nasdaq Capital Market. However, there is no guarantee that the reverse split will ensure compliance with the minimum bid price requirement.
Read more →ELABNorthstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preser
Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., has successfully submitted a pre-IND meeting request to the FDA for EL-22, an innovative obesity therapy targeting fat loss and muscle preservation. They anticipate a Type B pre-IND meeting in the second fiscal quarter of 2025, seeking guidance on their nonclinical studies and clinical development plans. Preclinical studies have shown promising results, and Northstrive aims to file an Investigational New Drug application in 2025 to begin clinical trials combining EL-22 with GLP-1 receptor agonists for obesity treatment.
Read more →ELABA PMGC HOLDINGS C OMPANY (NA SDAQ: ELAB) The information in this presentation is being provided so you can familiarize yourself with PMGC Holdings, Inc . ("PMGC", or the "Company," "we," "us," or "our") . We request that
PMGC Holdings, Inc. has introduced NorthStrive Biosciences, which focuses on therapeutic advancements for obesity and aesthetics. The company's lead asset, EL-22, is a first-in-class probiotic designed to preserve muscle during GLP-1 treatments. Early data indicates that EL-22 effectively inhibits muscle loss and enhances overall muscle strength. The firm is actively seeking additional assets and recruiting a specialized team for the development of its obesity-focused portfolio.
Read more →ELABPMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture Subtitle 1: Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency Newport Beach, CA
PMGC Holdings Inc. has announced the successful closing of the divestiture of its wholly owned subsidiary, Elevai Skincare Inc., to Carmell Corporation. This strategic move aims to reduce cash burn and enhance operational efficiency for PMGC. The transaction is expected to not only provide immediate financial benefits but also secure future upside through structured royalties and milestone payments. The divestiture represents a pivotal step in PMGC's efforts to maximize shareholder value and explore new growth opportunities.
Read more →ELABRESIGNATION LETTER To the Shareholders and Board of Directors of Elevai Labs Inc. Ladies and Gentlemen: This letter serves as notice that I hereby resign from my position as director of Elevai Labs Inc. My resignation is
Jordan R. Plews has submitted his resignation as a director of Elevai Labs Inc. The announcement states that the resignation is not due to any disagreements regarding the company's operations or policies. This unexpected departure could raise questions about stability and leadership within the organization.
Read more →ELABElevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance November 22nd, 2024
Elevai Labs Inc. announced a 1-for-200 reverse stock split effective November 27, 2024, in order to maintain compliance with Nasdaq's minimum bid price requirement. This action will consolidate the current shares into fewer shares without altering the overall value of shareholder equity. The company expresses optimism about its future and the potential for growth post-split. Adjustments will be made to stock options and awards to align with the new share structure.
Read more →ELABKNOTUS Co., Ltd. STUDY No. 21 - KE - 1021 Efficacy study of new drug candidate for sarcopenia Experiment protocol 1. Experiment group 2. Experiment schedule group sex Administration Amount r o u te (mL/head) material (n)
KNOTUS Co., Ltd. has conducted an efficacy study for a new drug candidate targeting sarcopenia. The study results indicate significant improvements in grip strength and muscle measures for certain test groups compared to the control group. Specifically, groups G2 and G3 exhibited increased grip strength, while G3 also showed enhanced latency in a motor function test. Notably, the length and weight analyses confirmed the superiority of groups G3, G4, and G5 over the control group.
Read more →ELABElevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
Elevai Labs Inc. has announced the pricing of a public offering expected to generate approximately $8.0 million in gross proceeds. The offering consists of approximately 28.57 million shares of common stock and includes warrants with defined exercise prices. The funds raised will primarily be used for general corporate purposes. The closing of the offering is anticipated by September 24, 2024, pending customary closing conditions. While this move positions Elevai for growth in the medical aesthetics sector, it does come with inherent risks and a reliance on the success of its product candidates.
Read more →ELABNation a N l Hair loss Medical Aesthetics President Carly Klein Today the #1 leading cause of Alopecia is Genetics While hair loss is a common affliction for both men and women, there are two underlying causes, and sympt
Carly Klein, President of Nation a N l Hair Loss Medical Aesthetics, discusses the leading cause of alopecia, emphasizing that genetics is a significant factor. She highlights the importance of addressing underlying causes of hair loss and introduces the ELEVAI Root Renewal System, which combines exosome technology with microneedling for effective treatment. Clinical results showcase improvements in hair strength and density, indicating potential for reversing hair loss.
Read more →ELABElevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum
Elevai Labs Inc.'s subsidiary, Elevai Skincare Inc., has announced positive results from a completed clinical study on the Elevai Enfinity topical exosome serum. The study reported significant improvements in various skin appearance metrics, with results currently pending peer review. Conducted on 29 participants aged 40-70, the trial demonstrated safety and tolerability of the product over a 12-week duration. Elevai Skincare plans to share the full study results in the near future, marking a significant step in their commitment to the science of aesthetics.
Read more →ELABNEXT GENERATION SKIN & SCALP REJUVENATION: STEM CELL EXOSOMES + MITOCHONDRIAL BIOGENESIS TECHNOLOGY DISCOVERED USING AI Jordan R. Plews, PhD & Keshav K. Singh, PhD Jordan R. Plews, PhD Cofounder of ELEVAI Labs Inc. (Nasd
ELEVAI Labs Inc. has unveiled a next-generation skin and scalp rejuvenation technology that leverages stem cell exosomes and mitochondrial biogenesis, developed with the aid of artificial intelligence. This innovative treatment aims to enhance cellular communication and healing, particularly focusing on the impact of exosomes derived from younger cells. The technology promises significant improvements in skin rejuvenation by efficiently repairing signs of aging while maintaining a commitment to safe, animal-free processing techniques. These advancements represent a potential breakthrough in the cosmetic application of stem cell therapies.
Read more →ELABElevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments Agreement adds two drug candidates to product pipeline consisting of
Elevai Labs has entered an exclusive licensing agreement with MOA Life Plus Co., Ltd. to develop two novel drug candidates targeting obesity and muscle loss prevention. The licensed assets, EL-22 and EL-32, aim to improve obesity treatments by preserving muscle mass while facilitating fat loss, a common issue with existing GLP-1 therapies. Elevai plans to initiate clinical trials and submit an Investigational New Drug (IND) application in 2025 to further evaluate these assets' efficacy in conjunction with GLP-1 obesity treatments.
Read more →ELABELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchyma
ELEVAI Labs, Inc. has signed a worldwide licensing agreement with INmune Bio, Inc. for the use of proprietary 'EMx' stem cell manufacturing technology. This technology enables Elevai to produce high-quality, cGMP grade mesenchymal stromal cells at lower costs, promoting vertical manufacturing integration. The agreement emphasizes ethical sourcing and compliance with quality standards while allowing Elevai to expand its product portfolio in the medical aesthetics sector. Elevai aims to leverage this technology to enhance its competitive position in the industry.
Read more →ELABElevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
Elevai Labs, Inc. has entered into a licensing agreement with Yuva Biosciences to merge their respective technologies for developing new aesthetic products. The collaboration will focus on integrating Yuva's mitochondrial research with Elevai's precision regenerative exosome technology to create skincare formulations aimed at signs of aging. This partnership signifies a strategic effort to innovate within the cosmetics market and to potentially offer unique products. The move is seen as a way to enhance Elevai's existing offerings in the physician-dispensed skincare domain.
Read more →ELAB▲ +6.6%on this newsshared move
ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering Newport Beach, CA
ELEVAI Labs, Inc. successfully closed its initial public offering, raising $6 million by selling 1.5 million shares at $4 each. The company's shares are now trading on the Nasdaq Capital Market under the ticker ELAB, starting from November 21, 2023. Proceeds from the offering are earmarked for business expansion, enhancing market presence, and broadening the product range. The transaction was supported by co-underwriters Univest Securities, LLC and Webull Financial, LLC.
Read more →ELABELEVAI Labs, Inc. Announces Pricing of $6,000,000 Initial Public Offering Newport Beach, CA
ELEVAI Labs, Inc. has announced the pricing of its initial public offering (IPO), offering 1,500,000 shares of common stock at a price of $4.00 per share, aiming for total gross proceeds of $6,000,000. The shares will be listed on the Nasdaq Capital Market under the ticker symbol 'ELAB' and are set to commence trading on November 21, 2023. The IPO is expected to close around November 24, 2023, pending the fulfillment of customary closing conditions. This marks a significant step for ELEVAI Labs, which specializes in physician-dispensed skincare solutions.
Read more →Competitive Position
How ELAB ranks across every disease it competes inCompetitive Position is a premium feature
See how ELAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial